Delnova Unveils Partnership With Pace® Life Sciences To Boost Capabilities
DelNova’s partnership will enable clinical development of its lead candidate ReViVox® for the rescue of undesirable outcomes which may arise from a botulinum neurotoxin (BoNT) treatment such as Botox®. Pace® Life Sciences provides a full suite of contract CMC development, clinical trials materials manufacturing, and regulatory compliance, services to the biopharmaceutical industries. SAN DIEGO, Oct. […]
Delnova Unveils Partnership With Pace® Life Sciences To Boost Capabilities Read More »